What to know about rare B-cell malignancies in 2025.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Rare B-cell malignancies, including lymphomas, are challenging due to their rarity and aggressiveness.
• A high index of suspicion is crucial for timely diagnosis and specialized treatment.

Purpose of the Study:

• To discuss three rare lymphomas: plasmablastic lymphoma, lymphomatoid granulomatosis, and intravascular lymphoma.
• To highlight diagnostic features, treatment strategies, and prognostic factors for these conditions.

Main Methods:

• Review of clinical characteristics, diagnostic markers (e.g., CD20 expression, Epstein-Barr virus), and genetic alterations (e.g., MYC rearrangement).
• Discussion of current and emerging therapeutic approaches, including novel agents and chemoimmunotherapy.

Main Results:

• Plasmablastic lymphoma: aggressive, associated with immunosuppression (HIV), extranodal, Epstein-Barr virus-positive; novel agents show promise but relapsed prognosis is poor.
• Lymphomatoid granulomatosis: Epstein-Barr virus-driven, angiocentric, affects lungs primarily; treatment and prognosis depend on histologic grade.
• Intravascular lymphoma: characterized by proliferation in small vessels, nonspecific symptoms; early biopsy and R-CHOP therapy with CNS-directed treatment improve remission chances.

Conclusions:

• Effective management of rare B-cell lymphomas requires specialized approaches and a high index of suspicion.
• Advancements in targeted therapies are improving outcomes, yet challenges persist, particularly for relapsed or refractory disease.
• Ongoing research is vital for developing more effective treatments for these rare and aggressive hematologic malignancies.